Please login to the form below

Building trust in clinical trials whilst it is in the public eye

We’re all well aware that healthcare organisations are generally perceived to be untrustworthy. According to Edelman’s 2018 Trust Barometer, we even saw a clear global decline of public trust in pharma, biotech, hospitals, insurance and consumer health companies.

With the healthcare sector being in the spotlight on a global scale due to the COVID-19 pandemic, could perceptions be changing? Currently, healthcare is seen as the hero, a stark contrast to how it’s been hailed previously. A big barrier between the public and clinical research has always been low awareness. But again, the coronavirus outbreak has catapulted the importance of clinical trials into the public domain. With all this in mind, the clinical research space could be at turning point in regard to its relationship with the public at large. Now could be the right time to start building that much needed trust. But to approach this in the right way, it has to be meaningful. It has to be genuine, helpful and led entirely by patients’ wants and needs. In terms of improving communication, it’s all about quality, not quantity…

Understanding patient distrust

Before you begin to put a strategy in place to build trust with patients, you need to understand the causes of that distrust in the first place. Everyone will have their own concerns about the clinical trial experience. Some could simply be due to lack of awareness and knowledge, some could be due to previous experiences, and often, minority populations have little confidence in clinical trials demonstrating cultural competency.

One meaningful way to build trust with minority populations could be ensuring that clinical trial investigators come from diverse backgrounds. This will do much more than just pay lip service to the idea of working to understand cultural differences and requirements. It will put real people in the right place to ensure those needs are addressed and done so in an authentic way.

There’s already a clear lack of tracking, reporting and recognition of the ethnicities of coronavirus victims. Evidence is showing that a high proportion of victims are ethnic minorities, however not enough is being done fast enough to address this, including inclusion in COVID clinical trials. We’ve discussed the issue in more detail in a previous blog, which you can access here. But the crux of the matter is, that without action from those in the clinical research space to recognise and address the impact COVID-19 is having on ethnic minorities, the distrust that’s already there will only increase.

True transparency

Just as improving communication is essential to building trust, true transparency is essential to the effectiveness of that communication. This can begin with openly sharing details on everything from your innovations to your processes. Things like what was required to develop a drug, how were your challenges overcome, and what was your honest experience. While this kind of information isn’t essential to the public, it helps tell your story which is powerful for building credibility and trust. When it comes to communicating the real need-to-knows with patients, not disclosing the full story will soon become apparent and detrimental to your relationship. When providing details on what the trial experience will be like, what patients should expect, or the potential for successful treatment, honesty is vital. This can even stretch to allowing patients in trials to view and download certain clinical trial data and share with others, such as their primary care physician. Patients own their data, so in the spirit of true transparency, it shouldn’t be hidden from them. Across everything, patients’ questions should be answered honestly, clearly and preferably in the patient’s first language. Imagine if all the marketing content we created existed to simply answer to patients. Surely then we’ve done our job right?

Is social listening the first step?

Something that we’re finding really insightful here at COUCH Health is social listening. Social media is already recognised as a place to target patients with communications, but actually the most powerful thing you can use social media for is to listen to the discussions patients are having organically, unaware of your observation. Here, you can gather honest data to determine how patients feel about your trial or company. Plus, listening to patients’ genuine wants and needs means you can create communications that are most meaningful rather than your assumption of what they want.

Opportunities to build trust are endless

In this blog, we’ve only scratched the surface of what can be done to build trust. Other opportunities include creating messaging from company staff to give your communications greater credibility to the processes. Going one step further and opening up your laboratories to potential patients will showcase the work that’s being done and give people a better idea of why drugs can be so expensive. Lastly, providing support to patients beyond the clinical trial can do so much to build trust and reassurance. This can simply be helping to educate patients about their diseases and offering the tools and support structures to help manage them.

As awareness around clinical trials has heightened, there’s an opportunity to overcome a barrier that’s forever stood in the way of enrolment. The challenge will be ensuring that the newfound awareness isn’t also a catalyst for heightened distrust among certain populations.

This blog was originally published here:

14th October 2020



Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Suite 2.10, Jactin House
24 Hood Street
M4 6WX
United Kingdom

Latest content on this profile

COUCH Health publishes report to encourage patient engagement in the MedTech sector
Manchester, UK, 27 February 2023 — COUCH Health today announced the publication of a new report “The Power of Patient Engagement in MedTech”.
COUCH Health
#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need unconscious bias training.”
COUCH Health
How do ethnic minority groups in the U.S. view clinical trials?
This year, we decided to do the same with ethnic minority communities over in the United States (U.S.) too. Ultimately, we wanted to explore attitudes towards clinical trials from these communities, understand the barriers in participation, and determine what factors may influence people’s decisions to take part.
COUCH Health
Three things to consider when using social listening research for patient recruitment
We are looking at how patient research can power your patient recruitment campaign. A look into social listening follows on from this blog perfectly, offering a stronger and more authentic alternative to relying on data trends to guide your activities. So, let’s get started…
COUCH Health
4 ways mobile ethnography studies can elevate your patient insights
How can we achieve more real-life, in-the-moment insights from different groups to understand their thoughts and behaviours? This is where ethnography studies come in.
COUCH Health
#DemandDiversity: We’re calling on the clinical trials industry to include us all
The lack of diversity in clinical trials is something we’ve spoken about time and time again. By now, you might think we sound a bit like a broken record. But, the fact is, many people still aren’t aware of the underrepresentation, especially those who don’t work in the industry. Do you think if the clinical research industry could see the people they were leaving out of clinical trials, and hear how they felt about being underrepresented, it would make a difference?
COUCH Health